FDA Authorizes First Device to Continuously Monitor Glucose and Ketones

Why it matters locally: The authorization of this new monitoring device will directly benefit Minnesotans with diabetes, providing them with enhanced tools for managing their condition. Healthcare providers across the state, including those at Hennepin Healthcare Emergency Department, will be able to recommend and utilize this technology for patient care.

The U.S. Food and Drug Administration has authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System. This authorization marks the first time a wearable device has gained approval to continuously monitor both ketone levels and blood sugar. Individuals aged two years and older who live with diabetes can now use this system. The device provides continuous data on these two biomarkers.